Loading…
for educational and safety purposes
1cP-LSD and 1B-LSD both come up in the same conversations; they overlap on Serotonin. 1cP-LSD: 1cP-LSD (1-cyclopropanoyl-LSD) is a widely distributed lysergamide bearing a cyclopropylcarbonyl group on the indole nitrogen of LSD. 1B-LSD: 1B-LSD (1-butyryl-LSD) is a semisynthetic lysergamide bearing a four-carbon butyryl group on the indole nitrogen of lysergic acid diethylamide, distributed as a research chemical.
1cP-LSD (1-cyclopropanoyl-LSD) is a widely distributed lysergamide bearing a cyclopropylcarbonyl group on the indole nitrogen of LSD. Incubation with human serum generates LSD, indicating that it acts as a prodrug in vivo, and it induces the LSD-like head-twitch response in mice with a median effective dose comparable to 1P-LSD; the liberated LSD produces the classic serotonergic psychedelic experience through 5-HT2A receptor agonism. Because of its close correspondence to LSD, it has become one of the most popular legal-grey lysergamides and has even been the subject of exploratory low-dose veterinary studies examining anxiety and welfare in dogs. Analytical, metabolic, and in silico toxicological investigations have characterized its detection, stability, and predicted hazard profile.
1B-LSD (1-butyryl-LSD) is a semisynthetic lysergamide bearing a four-carbon butyryl group on the indole nitrogen of lysergic acid diethylamide, distributed as a research chemical. Pharmacological and biotransformation studies of 1-acyl-substituted LSD derivatives indicate that N1-acylation sharply lowers direct affinity and efficacy at 5-HT2A and related serotonin receptors, yet these compounds still evoke the head-twitch response in mice because they are rapidly deacylated in vivo to LSD; this supports classification of 1B-LSD as a prodrug. Once cleaved, the liberated LSD produces the characteristic serotonergic psychedelic state through 5-HT2A receptor agonism. Analytical and in silico toxicological work has since characterized its mass-spectral fingerprint, serum deacylation, and predicted organ-toxicity profile alongside related N1-acyl lysergamides.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
partial agonist (via LSD)
partial agonist (via LSD)
agonist
agonist
agonist
partial agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.